NL-OMON28176尚未招募不适用
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 90
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with pre-clinical RA, defined by the presence of arthralgia and at least one of the following features:
- •1. IgM-rheumatoid factor (IgM-RF) of > 12.5 IU/ml;
排除标准
- •1. Clinically evident arthritis;
- •2. History of arthritis;
研究者
相似试验
进行中（未招募）
不适用
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.EUCTR2009-010955-29-NLDivision of Clinically Immunology and Rheumatology, AMC
已完成
不适用
Primary prevention of rheumatoid arthritisMusculoskeletal DiseasesRheumatoid arthritisISRCTN73232918Jan van Breemen Instituut (Netherlands)80
招募中
不适用
Primary prevention of rheumatoid arthritis.rheumatoid arthritisNL-OMON26301Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut80
已完成
不适用
Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study)Rheumatoid arthritisJPRN-UMIN000001798Team RA, Rheumatosurgery, Osaka City University Medical School100
Unknown
4 期
Remission Induction in Very Early Rheumatoid ArthritisRheumatoid ArthritisNCT00523692University Hospital Birmingham20